Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination

Journal of Cellular Biochemistry

Volumn 113, Issue 5, 2012, Pages 1787-1799

  Yeung, Percy Luk ^a   Denissova, Natalia G ^a   Nasello, Cara ^a   Hakhverdyan, Zhanna ^a   Chen, J Don ^b,c   Brenneman, Mark A ^a,c  

^a Life Sciences Building Rutgers University   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

ACUTE PROMYELOCYTIC LEUKEMIA; ALL TRANS RETINOIC ACID; ARSENIC TRIOXIDE; DNA REPAIR; HOMOLOGOUS RECOMBINATION; PML NUCLEAR BODIES

Indexed keywords

HISTONE H2AX; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RAD51 PROTEIN; RETINOIC ACID RECEPTOR ALPHA; SINGLE STRANDED DNA;

ARTICLE; CANCER INHIBITION; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR GENE;

ARSENICALS; CELL NUCLEUS; DNA BREAKS, DOUBLE-STRANDED; DNA END-JOINING REPAIR; DNA, NEOPLASM; GENOMIC INSTABILITY; HISTONES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; PHOSPHORYLATION; RAD51 RECOMBINASE; RECOMBINATIONAL DNA REPAIR; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84859047067     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24050     Document Type: Article

References (58)

1. Allen C, Halbrook J, Nickoloff JA,. 2003. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 1: 913-920. (Pubitemid 37288709)
2. Beech SJ, Lethbridge KJ, Killick N, McGlincy N, Leppard KN,. 2005. Isoforms of the promyelocytic leukemia protein differ in their effects on ND10 organization. Exp Cell Res 307: 109-117. (Pubitemid 40732737)
3. Bernardi R, Pandolfi PP,. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8: 1006-1016. (Pubitemid 350174636)
4. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP,. 2004. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6: 665-672. (Pubitemid 38960925)
5. Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J,. 2001. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol 153: 367-380. (Pubitemid 34280221)
6. Bøe SO, Haave M, Jul-Larsen A, Grudic A, Bjerkvig R, Lønning PE,. 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. J Cell Sci 119: 3284-3295. (Pubitemid 44405214)
7. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM,. 1997. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 2551-2556. (Pubitemid 27136913)
8. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR,. 1995. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240-4248.
9. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z,. 1996. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061. (Pubitemid 26333331)
10. D'Andrea AD,. 2010. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 362: 1909-1919.
11. Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG, Bazett-Jones DP,. 2006a. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol 175: 55-66. (Pubitemid 44537198)
12. Dellaire G, Ching RW, Dehghani H, Ren Y, Bazett-Jones DP,. 2006b. The number of PML nuclear bodies increases in early S phase by a fission mechanism. J Cell Sci 119: 1026-1033.
13. Dellaire G, Farrall R, Bickmore WA,. 2003. The Nuclear Protein Database (NPD): sub-nuclear localisation and functional annotation of the nuclear proteome. Nucleic Acids Res 31: 328-330. (Pubitemid 36157283)
14. Duprez E, Lillehaug JR, Naoe T, Lanotte M,. 1996. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. Oncogene 12: 2451-2459. (Pubitemid 26192727)
15. Eladad S, Ye TZ, Hu P, Leversha M, Beresten S, Matunis MJ, Ellis NA,. 2005. Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum Mol Genet 14: 1351-1365. (Pubitemid 40744493)
16. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G,. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195.
17. Gatz SA, Wiesmüller L,. 2006. p53 in recombination and repair. Cell Death Differ 13: 1003-1016.
18. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP,. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96: 269-279. (Pubitemid 38256272)
19. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y,. 2009. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 69: 4818-4826.
20. Helleday T,. 2010. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31: 955-960.
21. Henson JD, Neumann AA, Yeager TR, Reddel RR,. 2002. Alternative lengthening of telomeres in mammalian cells. Oncogene 21: 598-610. (Pubitemid 34146260)
22. Heyer WD,. 2004. A new deal for Holliday junctions. Nat Struct Mol Biol 11: 117-119.
23. Hromas R, Wray J, Lee SH, Martinez L, Farrington J, Corwin LK, Ramsey H, Nickoloff JA, Williamson EA,. 2008. The human set and transposase domain protein Metnase interacts with DNA Ligase IV and enhances the efficiency and accuracy of non-homologous end-joining. DNA Repair 7: 1927-1937.
24. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S, Chen Z, Chen SJ,. 1993. Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 82: 1264-1269. (Pubitemid 23254002)
25. Isakson P, Bjoras M, Boe SO, Simonsen A,. 2010. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 116: 2324-2331.
26. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF 3rd, Maul GG,. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221-234.
27. Jensen K, Shiels C, Freemont PS,. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233. (Pubitemid 33105011)
28. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RPJ, Miller WHJ,. 2001. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 98: 2651-2656.
29. Kakizuka A, Miller WHJ, Umesono K, Warrell RPJ, Frankel SR, Murty VV, Dmitrovsky E, Evans RM,. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674. (Pubitemid 121001702)
30. Lallemand-Breitenbach V, de The H,. 2010. PML nuclear bodies. Cold Spring Harb Perspect Biol 2: a000661.
31. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R,. 1991. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086.
32. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ, Chen JD,. 2000. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol 20: 1784-1796. (Pubitemid 30100196)
33. Lin DY, Lai MZ, Ann DK, Shih HM,. 2003. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem 278: 15958-15965. (Pubitemid 36799714)
34. Lio Y-C, Schild D, Brenneman MA, Redpath JL,. J. CD. 2004. Human RAD51C deficiency destabilizes XRCC3, impairs recombination and radiosensitizes S/G2-phase cells. J Biol Chem 279: 42313-42320. (Pubitemid 39313680)
35. Liu J, Song Y, Qian J, Liu B, Dong Y, Tian B, Sun Z,. 2011. Promyelocytic leukemia protein interacts with Werner syndrome helicase and regulates double-strand break repair in gamma-irradiation-induced DNA damage responses. Biochemistry (Moscow) 76: 550-554.
36. Lu H, Guo X, Meng X, Liu J, Allen C, Wray J, Nickoloff JA, Shen Z,. 2005. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol 25: 1949-1957. (Pubitemid 40280157)
37. Melnick A, Licht JD,. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215. (Pubitemid 29220886)
38. Miller WHJ, Kakizuka A, Frankel SR, Warrell RPJ, DeBlasio A, Levine K, Evans RM, Dmitrovsky E,. 1992. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89: 2694-2698.
39. Otterlei M, Bruheim P, Ahn B, Bussen W, Karmakar P, Baynton K, Bohr VA,. 2006. Werner syndrome protein participates in a complex with RAD51, RAD54, RAD54B and ATR in response to ICL-induced replication arrest. J Cell Sci 119: 5137-5146. (Pubitemid 46085192)
40. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Rochette-Egly C, Gaube MP, Chambon P, Pelicci PG,. 1992. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J 11: 1397-1407.
41. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, Venkitaraman AR,. 2002. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420: 287-293. (Pubitemid 35398178)
42. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L,. 2003. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401-406. (Pubitemid 36278858)
43. Shrivastav M, Miller CA, De Haro LP, Durant ST, Chen BP, Chen DJ, Nickoloff JA,. 2009. DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair 8: 920-929.
44. Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S,. 2008. HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res 68: 9954-9963.
45. Takizawa Y, Qing Y, Takaku M, Ishida T, Morozumi Y, Tsujita T, Kogame T, Hirota K, Takahashi M, Shibata T, Kurumizaka H, Takeda S,. 2010. GEMIN2 promotes accumulation of RAD51 at double-strand breaks in homologous recombination. Nucleic Acids Res 38: 5059-5074.
46. Tussie-Luna MI, Rozo L, Roy AL,. 2006. Pro-proliferative function of the long isoform of PML-RARa involved in acute promyelocytic leukemia. Oncogene 25: 3375-3386. (Pubitemid 43877041)
47. Vahdat L, Maslak P, Miller WHJ, Eardley A, Heller GASD, Warrell RPJ,. 1994. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84: 3843-3849.
48. Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G,. 2010. PML down-regulation in soft tissue sarcomas. J Cell Physiol 224: 644-648.
49. Vitoux D, Nasr R, de Thé H,. 2007. Acute promyelocytic leukemia: New issues on pathogenesis and treatment response. Int J Biochem Cell Biol 39: 1063-1070. (Pubitemid 46819138)
50. Wang H, Chen XY, Wang BS, Rong ZX, Qi H, Chen HZ,. 2011. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk Res 35: 1170-1177.
51. Wang JG, Barsky LW, Davicioni E, Weinberg KI, Triche TJ, Zhang XK, Wu L,. 2006. Retinoic acid induces leukemia cell G1 arrest and transition into differentiation by inhibiting cyclin-dependent kinase-activating kinase binding and phosphorylation of PML/RARalpha. FASEB J 20: 2142-2144.
52. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP,. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551. (Pubitemid 28217080)
53. Wang ZY, Chen Z,. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.
54. Wu L, Hickson ID,. 2003. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature 426: 870-874. (Pubitemid 38056876)
55. Xu ZX, Timanova-Atanasova A, Zhao RX, Chang KS,. 2003. PML colocalizes with and stabilizes the DNA damage response protein TopBP1. Mol Cell Biol 23: 4247-4256. (Pubitemid 36666427)
56. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR,. 1999. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59: 4175-4179. (Pubitemid 29418720)
57. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z,. 2010. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243.
58. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP,. 1999. A role for PML and the nuclear body in genomic stability. Oncogene 18: 7941-7947. (Pubitemid 30050554)